A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE012 (BRA) · Dr. Kowalski
consented 2023-05-01
Adverse events
Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-08-22 (study day 95); relationship: N
Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-09-15 (study day 119); relationship: N
Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-11-23 (study day 188); relationship: not assessed
Grade 1 Fatigue — outcome: RECOVERED/RESOLVED; onset 2024-01-13 (study day 239); relationship: N
Grade 1 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2024-05-01 (study day 348); relationship: not assessed
Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2024-11-16 (study day 547); relationship: not assessed
Data queries
No data queries.